𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sarbanes-Oxley update: Where are we today?

✍ Scribed by Robert W. Rouse; Thomas R. Weirich; Wendy M. Hambleton

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
78 KB
Volume
16
Category
Article
ISSN
1044-8136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

It has been over two years since Congress passed the Sarbanes‐Oxley Act (SOX) in an effort to restore investor confidence in the financial reporting of publicly held companies. So what has really changed? What is the situation today? The authors examine the aftermath of SOX and the latest guidance for companies struggling to comply. © 2005 Wiley Periodicals, Inc.

📜 SIMILAR VOLUMES

Lipid formulations of amphotericin B: wh
Lipid formulations of amphotericin B: where are we today?
✍ A. Antoniadou; B. Dupont 📂 Article 📅 2005 🏛 Masson Editeur 🌐 French ⚖ 206 KB

Amphotericin B deoxycholate (AmBD) was introduced 45 years ago for the treatment of invasive mycoses, on the basis of open-label non comparative data. Throughout these years of use it proved to be a life-saving drug but also a toxic compound which under current approval criteria might not meet licen